Odense, Denmark – July 23, 2026 – Inverna Therapeutics is pleased to announce its participation in NLSDays on the 8th – 9th of October 2026 in Stockholm, Sweden. The event is a forum for innovative companies and academic researchers as well as mid-sized and big pharma companies to showcase their innovations to an audience of top-tier investors, life science industry executives, and potential partners.
“We look forward to presenting our portfolio and scientific progress in pursuit of new strategic partnerships and potential funding or licensing opportunities that can drive our business forward. NLSDays is the perfect global partnering and investment event for this.”
said Poul Sørensen, CEO of Inverna Therapeutics.
Inverna’s CEO Poul Sørensen welcomes meeting requests through the respective partnering platforms.
About Inverna Therapeutics
Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.
Contact :
- Poul Sørensen, CEO of Inverna Therapeutics
- psorensen@invernatx.com
